Multiple domestic new crown drugs enter clinical trials

The reporter learned from the State Council’s Joint Prevention and Control Mechanism Scientific Research Team that China’s self-developed new crown drug has completed phase III clinical trials and is applying for conditional listing

From the hundreds of antibodies isolated from the blood of convalescent patients, 2 strains of antibodies with high activity and strong complementarity were screened-the new coronavirus antibody combination drug BRII developed by Tsinghua University, Shenzhen Third People's Hospital and Tengsheng Biopharmaceutical team -196/BRII-198, has recently completed the foreign phase III clinical trials, and has been urgently called by the relevant departments to provide clinical treatment for more than 800 cases of infection in China

The neutralizing antibody JS016, jointly developed by the Institute of Microbiology of the Chinese Academy of Sciences and Shanghai Junshi Biotechnology, has also completed the international multi-center phase II clinical trial in November, and the current data show that it has achieved positive effects

According to another report, the new generation of androgen receptor antagonist prokruamide of Suzhou Kaifeng Pharmaceutical and Azivudine of Henan Normal University are carrying out phase III clinical trials at home and abroad, and the neutralizing antibody BGB of Peking University and Beijing Danxu -DXP-604 and FB2001 and VV116 of Shanghai Institute of Materia Medica, Chinese Academy of Sciences are also in the development process